ClinicalTrials.gg
RecruitingNCT06743607SUReUpdated Mar 31, 2026

Spinal Stimulation for Upper Extremity Recovery in the Home

An interventional study of Immediate Intervention and Waitlist control in Cervical Spinal Cord Injury, sponsored by Craig Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Craig Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Spinal Cord Injuries by Craig Hospital — 6 open to participants now, 7 under way, none of them phase 3. Spinal Cord Injuries · Craig Hospital.

Planned enrollment
7th of 17
46 · median 37
Started
2025
with 3 others
No phase
14 of 21
3 open now
Registered
19th of 21
by date

Among the 21 studies in Spinal Cord Injuries by Craig Hospital, this one is the 7th largest by planned enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2025, is one of 14 with no phase, and was the 19th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

6 of the 21 studies in Spinal Cord Injuries by Craig Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Spinal Cord Injuries by Craig Hospital, or all of them as a file.
02

Study summary

The purpose of this research is to evaluate the safety, feasibility, and tolerability of non-invasive spinal stimulation used in the home and/or community in combination with a functional home exercise program for the upper extremities (arm/hand function) as well as their combined impacts on changes in upper extremity function. The expected duration of participation in this study is about 31-33 hours over a 13-25-week period. Enrollees in this study will be randomly assigned to one of two groups: 1) upper extremity functional task-specific training combined with non-invasive transcutaneous spinal stimulation, or 2) waitlist control, which involves the same intervention, but with a 12-week delayed start. Participants complete initial testing (one time if in group one and three times [at weeks 0, 8, and 12] if in group two), 24 1-hour training sessions (2x/week in home with caregiver/companion support and 1x/week with research team in person or via video conference for 8 weeks), a post-treatment evaluation, and a final evaluation (4 weeks after post-treatment).

03

Conditions studied

  • Cervical Spinal Cord Injury
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 or older
  • History of traumatic SCI
  • Less than 12 months post SCI
  • SCI injury level C1-C8
  • SCI categorized as AIS B-D
  • Have passive range of motion (ROM) within functional limits at wrists, shoulders, and elbows
  • Have caregiver support to attend three in-person sessions and ongoing training at home
  • Have a caregiver who, in the judgment of the research team, is qualified to assist the participant in the safe use of TSS
  • Able to complete in-person training sessions and return to Craig Hospital for assessments
  • Experience no complicating physical or cognitive conditions as determined by their physician that would preclude the safe use of electrical stimulation
  • If using prescribed anti-spasticity medications, must be at a stable dose for at least four weeks prior to starting study procedures
  • Agrees to comply with devices instructions for use, protocol visits, and return of the device
  • Able to provide

Exclusion criteria

Exclusion Criteria:

  • Experience unstable chronic cardiac or respiratory complaints
  • Have a recent history of fracture, contractures, or skin pressure injuries that might interfere with the intervention
  • Received Botox injections to the UEs, neck, or hands within the last three months
  • Pregnant, planning to become pregnant, or currently breastfeeding
  • Have breakdown in skin area that will come into contact with electrodes
  • Prior nerve or tendon transfer procedure for the UEs
  • Concurrently are participating in another drug or device trial that may interfere with this study
  • Have an implanted pacemaker, spinal cord stimulator, ventriculoperitoneal shunt, deep brain stimulator, or intrathecal pump
  • In the opinion of the investigators, the study is not safe or appropriate for the participant
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
46 participants (estimated)

Study arms

  • Active comparator
    Immediate Intervention

    For the immediate intervention group, each participant will complete the following: * Initial baseline evaluation * 24 training sessions (3x/week for eight weeks) of UE Functional Task Practice (FTP)+TSS (two training sessions/week will be completed in the home with caregiver/companion support; the third weekly session will be conducted via videoconference with a research therapist) * Post-treatment evaluation (after eight weeks of training) and follow-up evaluation (four weeks after post-treatment evaluation). * Post-treatment and follow-up assessments will be conducted over two days: assessments completed without TSS on day one and with TSS on day two.

    Behavioral: Immediate Intervention

  • Active comparator
    Waitlist Control

    The waitlist control group will participate in a protocol similar to the immediate intervention group, except: * 12-week waiting period before starting the active intervention. * Assessments will be completed at 0, 8, and 12 weeks before starting the active intervention to control for spontaneous recovery. * Post-treatment evaluation (after eight weeks of training) * Follow-up assessment (four weeks after the post-treatment evaluation).

    Behavioral: Waitlist control

Interventions

  • BehavioralImmediate Intervention

    Participants will engage in a home exercise therapy program in combination with transcutaneous spinal stimulation intended to focus on the upper extremities that commences immediately after enrollment.

  • BehavioralWaitlist control

    Participants will engage in a home exercise therapy program in combination with transcutaneous spinal stimulation intended to focus on the upper extremities that commences 12 weeks after enrollment.

06

What researchers measure

Primary outcomes

  1. Capabilities of Upper Extremity Questionnaire (CUE-Q)

    The CUE-Q version 2.1 measures functional limitation and perceived difficulty of performing actions with upper extremities in individuals with tetraplegia. The CUE-Q has 32 items; each scored on a 1-to-7-point scale representing self-perceived difficulty with total scores ranging from 32 to 224 (higher scores demonstrating greater UE function) and right and left scores assessed separately

    Time frame: Weeks 0, 8, 12, 21, and 25

Secondary outcomes

  1. Graded Refined Assessment of Strength, Sensibility, and Prehension (GRASSP)

    This multimodal test measures sensorimotor and prehension function in three domains important in describing arm and hand function

    Time frame: Weeks 0, 8, 12, 21, and 25

  2. International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI)

    The ISNCSCI is a universal classification tool for SCI based on a standardized sensory and motor exam. The ISNCSCI involves a detailed examination to determine the sensory and motor levels for both the right and left sides, the overall neurological level of the injury, and the completeness of the injury as designated by the American Spinal Cord Injury Association (ASIA) Impairment Scale (AIS). The motor exam also results in a total Upper Extremity Motor Score (UEMS) ranging from 0 to 50, with higher scores indicative of greater UE strength.

    Time frame: Weeks 0, 8, 12, 21, and 25

  3. Pinch and Grasp Force

    Pinch and grasp force will be measured by the Commander Echo Console with the JTech Pinch and Hand Dynamometer to quantify finger and grasp strength.

    Time frame: Weeks 0, 8, 12, 21, and 25

  4. Global Rating of Change (GRC)

    The GRC assesses perceived change from an intervention. The scale is designed to quantify an individual's perceived improvement or deterioration over time. The magnitude of the change is then scored on a visual analog scale. GRC scales have been recommended for use as a core outcome measure in rehabilitation studies to improve the applicability of information from clinical trials to clinical practice.

    Time frame: Weeks 8, 12, 21, and 25

  5. Satisfaction with Treatment Scale

    The Satisfaction with Treatment Scale is a 6-point scale (0=strongly disagree; 5= strongly agree) used to rate satisfaction with treatment in previous intervention studies conducted in the home environment85 and will be modified specifically to address the transcutaneous spinal stimulation (TSS) intervention.

    Time frame: Weeks 8, 12, 21, and 25

  6. Qualitative Questions

    Participants and caregivers will be asked questions regarding their experience during the intervention, such as their likes and dislikes, notable changes or observations, and overall satisfaction with using TSS in their homes

    Time frame: Weeks 8 and 21

  7. Canadian Occupational Performance Measure (COPM)

    The COPM is an individualized, client-centered instrument designed to measure an individual's self-perception of physical functioning and satisfaction in the activities identified as important by the client. The COPM will directly assess the true importance of functional improvements with regard to the subject's ability to perform activities of daily living and/or to function occupationally.

    Time frame: Weeks 0, 8, 12, 21, and 25

  8. International Spinal Cord Injury Quality of Life Basic Data Set (QoL-BDS) Version 2.0

    This instrument measures self-reported quality of life across four domains: overall well-being, physical health, psychological health, and social life. For each domain, respondents are asked to rate their satisfaction on a 0-10 scale (0=completely dissatisfied; 10=completely satisfied).

    Time frame: Weeks 0, 8, 12, 21, and 25

  9. International Spinal Cord Injury Pain Basic Data Set (ISCIPBDS) Version 3.0

    This instrument identifies pain region, pain type (e.g., nociceptive, neuropathic), and treatments used to reduce pain in addition to pain intensity on a 0-10 scale (0=no pain; 10=pain as bad as you can imagine) and interference with various aspects of the respondent's life on a 0-10 scale (0=no interference; 10=extreme interference).

    Time frame: Weeks 0, 8, 12, 21, and 25

Other outcomes

  1. Demographic Information

    Demographic information will include: age, sex, race/ethnic background, pre-injury education, employment status, marital status, and living situation.

    Time frame: Week 0

  2. Injury Characteristics

    Injury information will include: date of injury, cause of injury, baseline AIS classification, and injury level.

    Time frame: Week 0

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Aug 2027, 27 months after the start.

Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 27 months is below that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
Dec 20, 2024
StartActual
May 28, 2025
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06743607
Lead sponsor
Craig Hospital
Collaborators
National Institute on Disability, Independent Living, and Rehabilitation Research
Responsible party
Candace Tefertiller (Executive Director of Research and Evaluation, Craig Hospital) — Principal investigator
First posted
Dec 20, 2024
Start date
May 28, 2025
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Mar 31, 2026

Study contacts

Candy Tefertiller, PT, DPT, PhD, NCS
Contact
ctefertiller@craighospital.org
303-789-8000
Bria Mellick, MS
Contact
bmellick@craighospital.org
303-789-8757

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion